PDF(Pubmed)
Abstract：
OBJECTIVE: This study aimed to evaluate the knowledge, attitude, and practice toward iron chelating agents (ICAs) in Iranian thalassemia major patients.
METHODS: A total of 101 patients with thalassemia major were involved in this cross-sectional survey. A deep medication review was done, and participants\' knowledge, attitude, and practice were evaluated by a validated instrument based on a 20-scoring system.
RESULTS: Statistical analyses showed 52 patients (51.5%) had a poor knowledge level (scores < 10) about their medications, 37 (36.6%) had a moderate level (scores 10-15), and 12 (11.9%) had a satisfactory level (scores > 15). Seventy-seven (76.2%) patients have positive beliefs regarding the dependence of their current health status on taking iron chelators, and 63 (62.4%) believed that they would become very ill without taking medication. The results also showed that the mean practice score in patients who received deferoxamine was 5.81 ± 3.50; in the patients who received deferiprone and those who received deferasirox, the mean scores were 7.36 ± 5.15 and 14.94 ± 4.14. Also, the knowledge and practice level had a direct linear correlation based on the regression analyses (P < 0.001).
CONCLUSIONS: In conclusion, results of the present research suggests that the patients\' knowledge about the administration, adverse events, and necessity of ICAs was not satisfactory. Improving the knowledge of thalassemia patients toward their medicines through educational interventions is highly recommended to improve their practice level.
METHODS: A total of 101 patients with thalassemia major were involved in this cross-sectional survey. A deep medication review was done, and participants\' knowledge, attitude, and practice were evaluated by a validated instrument based on a 20-scoring system.
RESULTS: Statistical analyses showed 52 patients (51.5%) had a poor knowledge level (scores < 10) about their medications, 37 (36.6%) had a moderate level (scores 10-15), and 12 (11.9%) had a satisfactory level (scores > 15). Seventy-seven (76.2%) patients have positive beliefs regarding the dependence of their current health status on taking iron chelators, and 63 (62.4%) believed that they would become very ill without taking medication. The results also showed that the mean practice score in patients who received deferoxamine was 5.81 ± 3.50; in the patients who received deferiprone and those who received deferasirox, the mean scores were 7.36 ± 5.15 and 14.94 ± 4.14. Also, the knowledge and practice level had a direct linear correlation based on the regression analyses (P < 0.001).
CONCLUSIONS: In conclusion, results of the present research suggests that the patients\' knowledge about the administration, adverse events, and necessity of ICAs was not satisfactory. Improving the knowledge of thalassemia patients toward their medicines through educational interventions is highly recommended to improve their practice level.
摘要：
目的：本研究旨在评估知识，态度,伊朗地中海贫血主要患者对铁螯合剂(ICAs)的治疗和实践。
方法：共有101例重型地中海贫血患者参与了这项横断面调查。进行了深入的药物审查，和参与者的知识，态度,和实践通过基于20评分系统的经过验证的仪器进行评估。
结果：统计分析显示52名患者（51.5%）对药物的知识水平较差（得分<10），37（36.6％）处于中等水平（得分10-15），12人(11.9%)达到满意水平(分数>15分)。77（76.2％）患者对其当前健康状况对服用铁螯合剂的依赖性有积极的信念，63人(62.4%)认为如果不服药，他们会病得很重。结果还表明，接受去铁胺治疗的患者的平均实践得分为5.81±3.50；在接受去铁酮治疗的患者和接受地拉罗司治疗的患者中，平均得分为7.36±5.15和14.94±4.14。此外，基于回归分析,知识水平与实践水平呈直接线性相关(P<0.001).
结论：结论：本研究的结果表明，患者对管理的知识，不良事件,国际注册会计师协会的必要性并不令人满意。强烈建议通过教育干预措施提高地中海贫血患者对药物的认识，以提高他们的实践水平。
方法：共有101例重型地中海贫血患者参与了这项横断面调查。进行了深入的药物审查，和参与者的知识，态度,和实践通过基于20评分系统的经过验证的仪器进行评估。
结果：统计分析显示52名患者（51.5%）对药物的知识水平较差（得分<10），37（36.6％）处于中等水平（得分10-15），12人(11.9%)达到满意水平(分数>15分)。77（76.2％）患者对其当前健康状况对服用铁螯合剂的依赖性有积极的信念，63人(62.4%)认为如果不服药，他们会病得很重。结果还表明，接受去铁胺治疗的患者的平均实践得分为5.81±3.50；在接受去铁酮治疗的患者和接受地拉罗司治疗的患者中，平均得分为7.36±5.15和14.94±4.14。此外，基于回归分析,知识水平与实践水平呈直接线性相关(P<0.001).
结论：结论：本研究的结果表明，患者对管理的知识，不良事件,国际注册会计师协会的必要性并不令人满意。强烈建议通过教育干预措施提高地中海贫血患者对药物的认识，以提高他们的实践水平。
